Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SNRS- Sunrise Technologies -- Ignore unavailable to you. Want to Upgrade?

To: BB BOB who wrote (2378)	5/8/1999 11:35:00 AM
From: sandbag	Read Replies (1) \| Respond to of 4140

"Does anyone know if this is optionable??" cboe.pcquote.com

To: BB BOB who wrote (2378)	5/11/1999 7:35:00 PM
From: Duke	Read Replies (1) \| Respond to of 4140

Hi Bob - This is an older post, however I think it should give u some perspective relative to your question. Good luck. This why I bought SNRS. 1st they own the patent for the treatment they are in process of getting approval from the FDA (Panel meeting scheduled July 22 or close to it). The process, as I understand, required to get such a patent requires 3 years. VISX is the only real competition for the treatment that SNRS is getting FDA approval for. And as I understand, there are no patents pending by individuals or companies in the hopper (please correct me if my DD is incorrect). Result 1) Pending FDA approval, they have a 3 year head start on similar treatment/s and given the speculation of a less expensive, more effective, final product than VISX; this is a very appealing proposition. Let's build on this: SNRS was able to attract and attain a chief scientist for the development of this technology who considered VISX 1st. THE entire management team was rebuilt and continues to attract "what's in it for me" real passionate PROFESSIONAL PIT BULLS. What To Worry About: FDA APPROVAL. Impending law suits to slow down market penetration and acceptance (A standard business tactic). (IMHO) That Swiss Report was a sampling of a discouraging tactic. However, expect more of the same... nature of the beast thing. What to be Pleased about: VISX's growing success and demand, only paves the way for SNRS.... Which reminds me that APL-9 is the ASCRS show where the unveiling will take place. Finally - Why did I buy SNRS, back in March of 97 for less than $1.5, and again in OCT-98 @ $4.5 then again in Dec-98 @ $7. I was told this story (from a source I respect and believe in) that I have just shared with you. And each time before I purchase more stock, this simple story is pretty much the same. However, what made the story believable then as it does now are the people behind SNRS; The Management Team. I looked into this and learned all of them come from winning professional backgrounds. Leaving very safe, profitable positions to take on this project. If you didn't know, SNRS only offers 1 product. It's all or none. This management team literally has put there collective professional ass on the line. They have much more to lose than salary or stock performance. This statement in itself left a strong impression. About a month ago I made a visit to the new location. Everywhere I looked (I was given an informal tour) everything I heard, even the beverage counter for visitors had "buying this stock was the right thing to do for me"; written all over it. Like I said: for me. I want to be clear that hyping this stock is not the intention here. I simply am sharing the road traveled in taking the risk I have chosen in buying SNRS. That ties all the loose ends. I hope this gives you a perspective of some value. And I hope the reason you choose to buy SNRS or any other stock is based on findings from "your" proven resources. RELEVANT NEWS REFERENCES: Monday May 10, 1999 Sunrise LTK System PMA Tentatively Scheduled for July FDA Advisory Panel Review, scheduled for review at the July 22-23 meeting of the FDA. biz.yahoo.com Wednesday May 5, 1999 Sunrise Technologies International, Inc. Announces Conversion of 12% Convertible Subordinated Pay-In-Kind Notes Issued In January 1998 biz.yahoo.com Tuesday May 4, 1999 Sunrise Technologies International, Inc. Receives Approval to Expand Study for Mid-Hyperopia - biz.yahoo.com Thursday April 1, 1999 PCX to Trade Options on Applied Science and Technology, Inc. and Sunrise Technologies Int'l, Inc. biz.yahoo.com Thursday April 1, 1999 OptiStock.com Ranks Top Performing Vision Care Stocks for Q1 1999 - Business Wire - 7:03 pm biz.yahoo.com Week of March 30 1999 SNRS has received conditional FDA approval to treat both eyes on the same day as the initial Sunrise laser thermal keratoplasty (LTK) treatment. jdigital.com Wednesday March 10, 1999 Sunrise Technologies International, Inc. Announces Restructuring - Business Wire - 11:01 am biz.yahoo.com Monday January 11, 1999 Sunrise Technologies International, Inc. Announces $10 Million Private Placement...will position the company for an expected 1999 launch in the United States of the Sunrise LTK System.... bigcharts.com ---------------------- 12-21-98 SUNRISE TECHNOLOGIES INTERNATIONAL Sunrise LTK System Sunrise Technologies International, Inc. has completed and submitted its pre-market approval application (PMA) to the U.S. FDA for its Sunrise LTK System for the treatment of hyperopia (+.75 - +2.50 diopters). news.pharmaceuticalonline.com 12-16-98 SUNRISE SEEKS FDA APPROVAL ON LASER Ophthalmic laser manufacturer Sunrise Technologies International Inc. has submitted its pre-market approval (PMA) application to the U.S. Food and Drug Administration (FDA), for its Sunrise LTK System for the treatment of hyperopia (+.75 -- +2.50 diopters). The PMA cohort includes results of clinical studies, featuring more than 345 cases. news.photonicsonline.com 12-4-98 SUNRISE Technologies, Inc. - Press Release - Press Release December 4, 1998 more press releases..SUNRISE TECHNOLOGIES INTERNATIONAL, INC. SUCCESSFULLY COMPLETES $11.8 MILLION PRIVATE PLACEMENT sunrise-tech.com 11-3-98 Sunrise Technologies International Inc., recently announced today that its premarket approval application should be submitted to the Food & Drug Administration (FDA) in the fourth quarter of 1998.Patient enrollment for t heir hyperopia trial for treatment ranges between 0.75 and 2.5 diopters was completed June 30, 1998. eyeinfo.com OPTISTOCK - WHO WE FOLLOW optistock.com